X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CIPLA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CIPLA DISHMAN PHARMA/
CIPLA
 
P/E (TTM) x 25.1 39.7 63.2% View Chart
P/BV x 3.3 3.7 91.7% View Chart
Dividend Yield % 0.7 0.5 143.1%  

Financials

 DISHMAN PHARMA   CIPLA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CIPLA
Mar-18
DISHMAN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs374663 56.5%   
Low Rs129479 26.9%   
Sales per share (Unadj.) Rs197.8189.0 104.6%  
Earnings per share (Unadj.) Rs21.217.6 120.5%  
Cash flow per share (Unadj.) Rs34.734.0 102.0%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.80.5 151.3%  
Book value per share (Unadj.) Rs179.9176.7 101.8%  
Shares outstanding (eoy) m80.69805.12 10.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.33.0 42.1%   
Avg P/E ratio x11.932.5 36.6%  
P/CF ratio (eoy) x7.216.8 43.2%  
Price / Book Value ratio x1.43.2 43.3%  
Dividend payout %9.417.1 55.3%   
Avg Mkt Cap Rs m20,306459,724 4.4%   
No. of employees `0000.823.6 3.5%   
Total wages/salary Rs m5,35526,901 19.9%   
Avg. sales/employee Rs Th19,252.76,446.1 298.7%   
Avg. wages/employee Rs Th6,459.51,139.4 566.9%   
Avg. net profit/employee Rs Th2,064.1600.0 344.0%   
INCOME DATA
Net Sales Rs m15,961152,193 10.5%  
Other income Rs m2653,577 7.4%   
Total revenues Rs m16,226155,769 10.4%   
Gross profit Rs m4,10328,264 14.5%  
Depreciation Rs m1,09113,228 8.2%   
Interest Rs m9441,142 82.7%   
Profit before tax Rs m2,33417,470 13.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-28 -4.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m6242,501 24.9%   
Profit after tax Rs m1,71114,166 12.1%  
Gross profit margin %25.718.6 138.4%  
Effective tax rate %26.714.3 186.7%   
Net profit margin %10.79.3 115.2%  
BALANCE SHEET DATA
Current assets Rs m11,018108,141 10.2%   
Current liabilities Rs m9,51738,322 24.8%   
Net working cap to sales %9.445.9 20.5%  
Current ratio x1.22.8 41.0%  
Inventory Days Days11097 113.9%  
Debtors Days Days3574 46.8%  
Net fixed assets Rs m16,304109,411 14.9%   
Share capital Rs m1611,610 10.0%   
"Free" reserves Rs m12,907140,682 9.2%   
Net worth Rs m14,516142,292 10.2%   
Long term debt Rs m4,18936,621 11.4%   
Total assets Rs m29,805228,606 13.0%  
Interest coverage x3.516.3 21.3%   
Debt to equity ratio x0.30.3 112.1%  
Sales to assets ratio x0.50.7 80.4%   
Return on assets %8.96.7 133.1%  
Return on equity %11.810.0 118.4%  
Return on capital %17.510.0 176.1%  
Exports to sales %24.832.8 75.6%   
Imports to sales %3.70-   
Exports (fob) Rs m3,95649,883 7.9%   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95251,691 9.6%   
Fx outflow Rs m69721,033 3.3%   
Net fx Rs m4,25530,658 13.9%   
CASH FLOW
From Operations Rs m2,78614,628 19.0%  
From Investments Rs m-1,529-8,540 17.9%  
From Financial Activity Rs m-941-3,855 24.4%  
Net Cashflow Rs m3162,431 13.0%  

Share Holding

Indian Promoters % 61.4 16.0 383.8%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.7 12.2 30.3%  
FIIs % 12.7 23.7 53.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 22.1 26.2 84.4%  
Shareholders   46,261 161,166 28.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - FDC LTD. COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS